10 completed, 4 recruiting, 2 terminated, 1 active not recruiting. 13 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 8, Recruiting 3, Terminated 2 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow BI 1291583: new trials by email Literature Review of BI 1291583 trials Research Report on BI 1291583
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the Blood Verducatib, Carbamazepine - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 20 | 2026-09-10 | 2026-09-23 |
| A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart Verducatib, Moxifloxacin, Placebo resembling Verducatib - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 56 | 2026-08-20 | 2026-09-09 |
| A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems BI 1291583 - Healthy, Hepatic Impairment | Phase 1 | Recruiting | Boehringer Ingelheim | 32 | 2025-07-17 | 2026-10-13 |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis BI 1291583, Placebo matching BI 1291583 - Bronchiectasis | Phase 3 | Recruiting | Boehringer Ingelheim | 1755 | 2025-06-09 | 2026-10-14 |
| A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood BI 1291583, erythromycin - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 20 | 2025-04-29 | 2025-09-16 |
| A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body dabigatran etexilate, BI 1291583 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 14 | 2025-01-23 | 2025-08-13 |
| A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations BI 1291583 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 30 | 2024-10-22 | 2025-08-13 |
| A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) BI 1291583, Placebo to BI 1291583 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Completed | Boehringer Ingelheim | 22 | 2024-04-05 | 2026-06-23 |
| A Study in Healthy Men to Test How BI 1291583 is Taken up by the Body BI 1291583, [14C]-BI 1291583 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 14 | 2023-12-12 | 2025-08-13 |
| Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine BI 1291583, Placebo matching BI 1291583 - Bronchiectasis | Phase 2 | Active not recruiting | Boehringer Ingelheim | 268 | 2023-09-08 | 2026-10-14 |
| A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis BI 1291583, Placebo - Bronchiectasis | Phase 2 | Completed | Boehringer Ingelheim | 322 | 2022-04-28 | 2026-07-28 |
| A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated BI 1291583, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 36 | 2022-02-04 | 2025-08-13 |
| A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated BI 1291583, Placebo - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2021-05-17 | 2025-08-13 |
| A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the Blood BI 1291583, Itraconazole - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 14 | 2019-04-12 | 2025-08-13 |
| A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are Tolerated BI 1291583, Placebo - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 24 | 2019-03-28 | 2025-08-13 |
| A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men BI 1291583 - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2019-02-27 | 2025-08-13 |
| This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated BI 1291583, Matching placebo: Tartaric acid - Healthy | Phase 1 | Terminated | Boehringer Ingelheim | 54 | 2018-02-05 | 2025-08-13 |
Bronchiectasis (4) · Cystic Fibrosis (1)
Boehringer Ingelheim (17)
Germany (14) · Netherlands (5) · United States (5) · Belgium (4) · France (4) · Italy (4) · Japan (4) · Spain (4) · Australia (3) · Bulgaria (3) · Canada (3) · Czechia (3) · Denmark (3) · Hungary (3) · Israel (3)
PMID 39175217, PMID 39255990, PMID 42820152
2018 (3), 2023 (3), 2017 (1)